# Evaluation in STEMI Patients Using FDY-5301

Study · id `cardio:ct-nct04837001` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04837001](<https://clinicaltrials.gov/study/NCT04837001>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04837001

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2351 participants.

## Technical summary

Registry record NCT04837001. Randomized; quadruple masking; primary purpose treatment. Start 2022-05-02 (actual); primary completion 2025-09-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2351 participants (enrolled count; ClinicalTrials.gov record NCT04837001, source copy `cardio:ctgov-nct04837001-2025-09-12`, retrieved 2026-10-26)
- Started: 2022-05-02 (actual) (ClinicalTrials.gov record NCT04837001, source copy `cardio:ctgov-nct04837001-2025-09-12`, retrieved 2026-10-26)
- Primary completion: 2025-09-03 (actual) (ClinicalTrials.gov record NCT04837001, source copy `cardio:ctgov-nct04837001-2025-09-12`, retrieved 2026-10-26)
- Completion: 2025-09-03 (actual) (ClinicalTrials.gov record NCT04837001, source copy `cardio:ctgov-nct04837001-2025-09-12`, retrieved 2026-10-26)
- Countries: United States; Canada; Hungary; Israel; Poland; Portugal (ClinicalTrials.gov record NCT04837001, source copy `cardio:ctgov-nct04837001-2025-09-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04837001-2025-09-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation in STEMI Patients Using FDY-5301
- Acronym: IOCYTE AMI-3
- Condition: Acute Myocardial Infarction
- Condition: STEMI
- Condition: Percutaneous Coronary Revascularization
- Intervention (Drug): FDY-5301
- Intervention (Other): Placebo
- Lead sponsor: Faraday Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: f845f1184b9b14a8c3d8b0eceaaf60d1e3ae22793ca855b6317b2ce7ef238272
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
